FIGURE 1

Synthesis of D4G Prodrug



i. Ac_2O/Pyridine/DMF 75° 4h; ii. $POCl_3/C_6H_5NEt_2/(n\text{-}Bu)_4N^+Cl^-/CH_3CN$, 100°, 10min; iii. NH_3/CH_3OH, r.t., 6h; iv. $(CH_3)_2C(OAc)COBr/CH_3CN$, r.t., 3 h; v. Zn/DMF, r.t., 40min; vi. $K_2CO_3/CH_3OH/H_2O$, r.t., 2h; vii. Cyclopropylamine/ C_2H_5OH, r.t..

FIGURE 2

Effects of Mycophenolic Acid on Anti-HIV Activity of Nucleosides



*Compounds are more active than what is normally observed because experiments were done using slowly dividing cells. Normally observed EC_{50} vaues in the absence of mycophenolic acid for Carbovir and ddI are 1.2 μM and 20 μM respectively.

FIGURE 3

Comparision of Synergy Between Abacavir/3TC and cyclo D4G/3TC



FIGURE 4

Effects of FDA Approved Nucleosides on the anti-HIV Activity of Cyclo D4G